Next Article in Journal
Special Issue: Left-Right Asymmetry and Cardiac Morphogenesis
Previous Article in Journal / Special Issue
Potential Impact of COMT-rs4680 G > A Gene Polymorphism in Coronary Artery Disease
Article Menu

Export Article

Open AccessReview
J. Cardiovasc. Dev. Dis. 2018, 5(3), 39;

Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects

Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Padua 35131, Italy
Author to whom correspondence should be addressed.
Received: 29 June 2018 / Revised: 10 July 2018 / Accepted: 11 July 2018 / Published: 14 July 2018
(This article belongs to the Special Issue Lipoprotein Metabolism and Atherosclerosis)
Full-Text   |   PDF [981 KB, uploaded 14 July 2018]   |  


Genetic and clinical studies have demonstrated that loss-of-function variants in the angiopoietin-like 3 (ANGPTL3) gene are associated with decreased plasma levels of triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), which leads to a significant reduction in cardiovascular risk. For this reason, ANGPTL3 is considered an important new pharmacological target for the treatment of cardiovascular diseases (CVDs) together with more conventional lipid lowering therapies, such as statins and anti proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies. Experimental evidence demonstrates that anti-ANGPTL3 therapies have an important anti-atherosclerotic effect. Results from phase I clinical trials with a monoclonal anti-ANGPTL3 antibody (evinacumab) and anti-sense oligonucleotide (ASO) clearly show a significant lipid lowering effect. In addition, from the analysis of the protein structure of ANGPTL3, it has been hypothesized that, beyond its inhibitory activity on lipoprotein and endothelial lipases, this molecule may have a pro-inflammatory, pro-angiogenic effect and a negative effect on cholesterol efflux, implying additional pro-atherosclerotic properties. In the future, data from phase II clinical trials and additional experimental evidence will help to define the efficacy and the additional anti-atherosclerotic properties of anti-ANGPTL3 therapies beyond the already available lipid lowering therapies. View Full-Text
Keywords: ANGPTL3; integrin; lipoprotein lipase; monoclonal antibodies; antisense oligonucleotide; atherosclerosis ANGPTL3; integrin; lipoprotein lipase; monoclonal antibodies; antisense oligonucleotide; atherosclerosis

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Lupo, M.G.; Ferri, N. Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects. J. Cardiovasc. Dev. Dis. 2018, 5, 39.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
J. Cardiovasc. Dev. Dis. EISSN 2308-3425 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top